Expanding upon prior surface‐modification strategies, Huang et al. engineered breast cancer–derived TEXs (HELA‐Exos)—a TEX vaccine platform derived from α‐lactalbumin–overexpressing breast cancer cells—electroporated to load the TLR3 agonist Hiltonol and the ICD inducer human neutrophil elastase (ELANE).[110] Upon systemic administration, HELA‐Exos demonstrated efficient tumor targeting, promoted CD8+ T cell–mediated cytotoxicity, and suppressed tumor progression in both orthotopic triple negative breast cancer (TNBC) models and patient‐derived tumor organoids. Here, CD8A is linked to breast carcinoma.